Thera-SAbDab

SILTUXIMAB

>   Structural Summary
TherapeuticSiltuximab
TargetIL6
Heavy ChainEVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS
Light ChainQIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center
Recorded Developmental Technologyna
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedCentocor Inc, Janssen Biotech, Memorial Sloan-Kettering Cancer Center
Conditions ApprovedGiant lymph node hyperplasia
Conditions ActiveMultiple myeloma
Conditions DiscontinuedParaproteinaemia, Myelodysplastic syndromes, Non-Hodgkin's lymphoma, Prostate cancer, Renal cell carcinoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]